1.
Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease : attrition rate and evolution of disease activity.
2.
3.
The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry : clues for the optimization of rituximab treatment strategies.
4.
5.
6.
7.
8.
The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice.
Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery.